Jornal brasileiro de nefrologia · 2026
Effect of lifestyle modification and atorvastatin on dyslipidemia and endothelial dysfunction markers in children with steroid resistant nephrotic syndrome.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kakkar Vanshika, Saha Abhijeet, Agrawal Prajal, Sharma Sunita, Nagia Anita, Singh Prachi, Pemde Harish K
Аннотация
INTRODUCTION: Persistent dyslipidemia in children with steroid resistant nephrotic syndrome (SRNS) causes endothelial dysfunction resulting in adverse cardiovascular outcomes.
METHODS: Thirty-four patients aged 4-18 years newly diagnosed with SRNS and no previous statin use were enrolled in this longitudinal observational study. Serum levels of total cholesterol, LDL cholesterol, and endothelial dysfunction markers (PSCK-9, E-selectin) were measured at baseline and after 12 weeks of lifestyle modifications in all patients, and atorvastatin was prescribed to those with LDL-cholesterol > 160 mg/dL. Primary outcome measure was change in plasma levels of total cholesterol, LDL cholesterol, PSCK-9, and E-selectin at 12 weeks. The secondary outcome was the correlation of PSCK-9 and E-selectin with lipid profile, blood pressure, BMI, serum albumin, and urine-protein creatinine ratio.
RESULTS: There was a significant decline in total cholesterol, LDL cholesterol, E-selectin, and PCSK-9 levels at 12 weeks of lifestyle modification and atorvastatin therapy. In a subgroup analysis between the statin group (n = 16) and the non-statin group (n = 18), both groups showed a significant decline in lipid profile parameters with a more pronounced decline in the statin subgroup. Endothelial dysfunction markers (E-selectin and PSCK-9) showed a declining trend in both subgroups, but the decline was not statistically significant in the statin group.
CONCLUSION: Dietary and lifestyle modifications led to a decline in endothelial dysfunction markers and an improvement in lipid profile. Statins helped improve dyslipidemia but did not significantly improve endothelial dysfunction markers at 12 weeks.
METHODS: Thirty-four patients aged 4-18 years newly diagnosed with SRNS and no previous statin use were enrolled in this longitudinal observational study. Serum levels of total cholesterol, LDL cholesterol, and endothelial dysfunction markers (PSCK-9, E-selectin) were measured at baseline and after 12 weeks of lifestyle modifications in all patients, and atorvastatin was prescribed to those with LDL-cholesterol > 160 mg/dL. Primary outcome measure was change in plasma levels of total cholesterol, LDL cholesterol, PSCK-9, and E-selectin at 12 weeks. The secondary outcome was the correlation of PSCK-9 and E-selectin with lipid profile, blood pressure, BMI, serum albumin, and urine-protein creatinine ratio.
RESULTS: There was a significant decline in total cholesterol, LDL cholesterol, E-selectin, and PCSK-9 levels at 12 weeks of lifestyle modification and atorvastatin therapy. In a subgroup analysis between the statin group (n = 16) and the non-statin group (n = 18), both groups showed a significant decline in lipid profile parameters with a more pronounced decline in the statin subgroup. Endothelial dysfunction markers (E-selectin and PSCK-9) showed a declining trend in both subgroups, but the decline was not statistically significant in the statin group.
CONCLUSION: Dietary and lifestyle modifications led to a decline in endothelial dysfunction markers and an improvement in lipid profile. Statins helped improve dyslipidemia but did not significantly improve endothelial dysfunction markers at 12 weeks.